NPO Petrovax Pharm presented the results of clinical trials for the first Russian-made quadrivalent vaccine for influenza prevention at the Sixth ESWI Influenza Conference.
“Grippol® Quadrivalent is the most advanced existing influenza vaccine with high preventive efficacy and safety which, simultaneously, protects against four strains of influenza virus,” said Marina Abramova, Vice President – Research, Development and Implementation of Medicines at NPO Petrovax Pharm. “The vaccine contains Polyoxidonium, an immunoadjuvant that contributes to the development of persistent immune response and ensures high safety profile.” The vaccine will be manufactured in Russia under a full-cycle technology from the stage of substance production. “The clinical trials in adults have been successfully completed, and their results confirmed the efficacy and safety of Grippol® Quadrivalent and its compliance with international criteria of EMA CPMP,” said Marina Abramova.
The company submitted the documents for state registration to the Ministry of Health of the Russian Federation. In 2018, the vaccine will be launched in the Russian market. The potential output will be up to 40 million doses a year.
WHO has been recommending vaccination with quadrivalent influenza vaccines as early as from 2012. In the world, only five countries, including Australia, USA, Canada, Germany, and France, are manufacturing quadrivalent vaccines. Russia will become the sixth country with its own independent manufacturing of such vaccines.